Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer:targeting the androgen receptor-regulated tumor immune microenvironment

摘要

Castration-resistant prostate cancer(CRPC)poses a major treatment challenge,because disease progression occurs despite androgen deprivation therapy(ADT)1.Overcoming therapeutic resistance in CRPC remains a critical unmet need in clinical practice.The androgen receptor(AR)signaling pathway plays a critical role in prostate cancer development and progression,and is also involved in regulating the tumor immune microenvironment(TIME).